118. 脊髄髄膜瘤 Myelomeningocele Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 4) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 10
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04652908 (ClinicalTrials.gov) | June 21, 2021 | 25/11/2020 | Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial | Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele | Myelomeningocele | Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix;Other: Untreated contemporaneous cohort | Diana Lee Farmer | California Institute for Regenerative Medicine (CIRM) | Recruiting | 19 Weeks | 25 Weeks | All | 55 | Phase 1/Phase 2 | United States |
| 2 | NCT04738539 (ClinicalTrials.gov) | March 2, 2021 | 1/2/2021 | Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies | Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies | Myelomeningocele;Neurogenic Bladder;Tethered Cord Syndrome;Bladder, Neurogenic;Urologic Diseases;Neurologic Dysfunction | Drug: Contrast Enhanced Voiding Urosonography with Urodynamic Testing;Diagnostic Test: Urodynamic Testing | University of Virginia | NULL | Recruiting | N/A | 18 Years | All | 105 | United States | |
| 3 | JPRN-UMIN000040088 | 2019/07/01 | 07/04/2020 | Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele | Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele - Safety Assessment Clinical Test of Fetal Surgery for Myelomeningocele | Myelomeningocele | MMC(Myelomeningocele) open fetal surgery | OSAKA UniversityDepartment of MedicineDivision of Obstetrics and Gynecology | NULL | Recruiting | 20years-old | Not applicable | Female | 15 | Not selected | Japan |
| 4 | NCT04468568 (ClinicalTrials.gov) | October 1, 2017 | 1/3/2020 | In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline | Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele | Myelomeningocele;Terbutaline Adverse Reaction;Pregnancy; Malformation Central Nervous System | Drug: Atosiban;Drug: Terbutaline | University of Sao Paulo General Hospital | NULL | Completed | 18 Years | 40 Years | Female | 25 | Brazil | |
| 5 | NCT00175123 (ClinicalTrials.gov) | May 2005 | 9/9/2005 | Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele | Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele | Myelomeningocele;Bladder, Neurogenic | Drug: Botulinum A toxin | University of Aarhus | Aarhus University Hospital | Active, not recruiting | 2 Years | 16 Years | Both | 30 | Phase 4 | Denmark |